SEC Tracker
Get the app

Moleculin Biotech MBRX

Moleculin Biotech (MBRX) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period. The filing highlights the company's progress in advancing its drug development pipeline and financial position, which is crucial for investors to assess Moleculin's short-term progress and long-term prospects.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Moleculin Biotech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  3. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  4. Biovie BIVI public float $8M, Dec 31, 2025
  5. Artelo Biosciences ARTL public float $9M, Jun 30, 2025